{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:46:25Z","timestamp":1776141985530,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dmd.2026.100247","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:29:03Z","timestamp":1770078543000},"page":"100247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining the novel all-human co-cultured hepatocytes system with physiologically based pharmacokinetic modeling to assess the translatability of cytochrome P450 and uridine 5\u2032-diphospho-glucuronosyltransferase induction data"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2143-6706","authenticated-orcid":false,"given":"Alessandra","family":"Pugliano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynur","family":"Ekiciler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil John","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10\u201311","key":"10.1016\/j.dmd.2026.100247_bib1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/00498250701534893","article-title":"Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations","volume":"37","author":"Hewitt","year":"2007","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.dmd.2026.100247_bib2","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bcp.2008.05.020","article-title":"Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor","volume":"77","author":"K\u00f6hle","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"11\u201312","key":"10.1016\/j.dmd.2026.100247_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.drudis.2012.01.017","article-title":"Reactions and enzymes in the metabolism of drugs and other xenobiotics","volume":"17","author":"Testa","year":"2012","journal-title":"Drug Discov Today"},{"issue":"8","key":"10.1016\/j.dmd.2026.100247_bib7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non-cytochrome P450-mediated metabolism in Food and Drug Administration-approved oral and intravenous drugs: 2006-2015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100247_bib8","series-title":"Guideline on the investigation of drug interactions","year":"2012"},{"key":"10.1016\/j.dmd.2026.100247_bib9","series-title":"In vitro drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions","year":"2020"},{"key":"10.1016\/j.dmd.2026.100247_bib10","article-title":"International Council for Harmonization of Technical Requirements for Pharmaceutical for Human Use","year":"2024","journal-title":"M12 drug interaction studies \u2013 guidance for industry"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/dmd.122.001132","article-title":"Quantitative cytochrome P450 3A4 induction risk assessment using human hepatocytes complemented with pregnane X receptor-activating profiles","volume":"51","author":"Ekiciler","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.3625","article-title":"ICH M12 drug interaction studies: summary of the efforts to achieve global convergence","volume":"118","author":"Reynolds","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100247_bib13","article-title":"M12 drug interaction studies","year":"2024","journal-title":"guidance for industry"},{"key":"10.1016\/j.dmd.2026.100247_bib14","series-title":"Cross discipline team leader review","year":"2016"},{"issue":"8","key":"10.1016\/j.dmd.2026.100247_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/pharmaceutics17081085","article-title":"Physiologically based pharmacokinetic modeling to assess perpetrator and victim cytochrome P450 2C induction risk","volume":"17","author":"Slavsky","year":"2025","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.dmd.2026.100247_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1124\/dmd.116.074567","article-title":"Considerations from the IQ induction working group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 positive control","volume":"45","author":"Hariparsad","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100052","article-title":"Quantitative clinical risk assessment of CYP2C, UDP-glucuronosyltransferase, P-glycoprotein induction, and complex drug-drug interactions using TruVivo human hepatocyte triculture platform","volume":"53","author":"Ramsden","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100247_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105504","article-title":"The morphology, functionality, and longevity of a novel all human hepatic cell-based tri-culture system","volume":"86","author":"Weaver","year":"2023","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.2503","article-title":"Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: an industry perspective","volume":"112","author":"Hariparsad","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.120.000055","volume":"49","author":"Wong","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100247_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106309","article-title":"Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling","volume":"179","author":"Moreira","year":"2022","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cpt.3477","article-title":"Building confidence in physiologically based pharmacokinetic modeling of CYP3A induction mediated by rifampin: an industry perspective","volume":"117","author":"Reddy","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100247_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100886","article-title":"Characterization of a novel human hepatocyte model, truvivoTM for the projection of clinical induction of drug metabolizing enzymes","volume":"55","author":"Slavsky","year":"2024","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmd.2026.100247_bib27","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/cts.13357","article-title":"Alternatives to rifampicin: a review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies","volume":"15","author":"Bolleddula","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100247_bib28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425255.2012.685237","article-title":"Role of CAR and PXR in xenobiotic sensing and metabolism","volume":"8","author":"Wang","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-020-03057-x","article-title":"A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management","volume":"77","author":"Yang","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100247_bib30","article-title":"Effectiveness and safety of the coadministration of rifampin and warfarin versus direct oral anticoagulants: a cohort study","volume":"2024","author":"Wung","year":"2024","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100247_bib31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100247_bib32","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.112.050583","article-title":"Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin","volume":"41","author":"Varma","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.108.025726","article-title":"Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine","volume":"37","author":"Stresser","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/dmd.112.047118","article-title":"Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy","volume":"41","author":"Dickmann","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"10.1016\/j.dmd.2026.100247_bib35","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJM198106113042405","article-title":"Quinidine-rifampin interaction","volume":"304","author":"Twum-Barima","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/clpt.2014.83","article-title":"Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots","volume":"96","author":"Bosilkovska","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/clpt.2011.247","article-title":"Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot","volume":"91","author":"Daali","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100247_bib39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mcp.2000.111183","article-title":"Rifampin decreases the plasma concentrations and effects of repaglinide","volume":"68","author":"Niemi","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-004-0746-z","article-title":"Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide","volume":"60","author":"Bidstrup","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0091270003253704","article-title":"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide","volume":"43","author":"Hatorp","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/DMDI.2003.19.4.287","article-title":"Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers","volume":"19","author":"Jayasagar","year":"2003","journal-title":"Drug Metabol Drug Interact"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/00498254.2020.1867330","article-title":"Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug","volume":"51","author":"Miura","year":"2021","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.dmd.2026.100247_bib44","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"53","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-021-04292-4","article-title":"Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants","volume":"88","author":"Ogasawara","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2125.2005.02515.x","article-title":"Effect of rifampicin on the pharmacokinetics of pioglitazone","volume":"61","author":"Jaakkola","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clpt.2003.10.003","article-title":"Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects","volume":"75","author":"Park","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100247_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clpt.2004.05.001","article-title":"Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone","volume":"76","author":"Niemi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bcpt.14095","article-title":"Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios","volume":"135","author":"Abouir","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100247_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","article-title":"Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity","volume":"80","author":"Loboz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0091270008314254","article-title":"Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity","volume":"48","author":"Kharasch","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/clpt.1987.168","article-title":"The mechanism of the warfarin-rifampin drug interaction in humans","volume":"42","author":"Heimark","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib54","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100247_bib55","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00228-018-2533-2","article-title":"Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9\/3A4 inducer, in healthy subjects","volume":"74","author":"Gardin","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cpt.3332","article-title":"Identification of a safe and tolerable carbamazepine dosing paradigm that facilitates effective evaluation of CYP3A4 induction","volume":"116","author":"Datta-Mannan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100247_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2125.1997.00630.x","article-title":"Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19","volume":"44","author":"Bertilsson","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100247_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00004714-199510000-00004","article-title":"Carbamazepine but not valproate induces bupropion metabolism","volume":"15","author":"Ketter","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.1072","article-title":"Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100247_bib60","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2125.1990.tb05457.x","article-title":"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids","volume":"30","author":"Crawford","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100247_bib61","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.dmd.2026.100247_bib62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2011.03118.x","article-title":"Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"52","author":"Bullman","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.dmd.2026.100247_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:57:15Z","timestamp":1776139035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0090955626000164"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100247","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining the novel all-human co-cultured hepatocytes system with physiologically based pharmacokinetic modeling to assess the translatability of cytochrome P450 and uridine 5\u2032-diphospho-glucuronosyltransferase induction data","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100247"}}